About the Company
We do not have any company description for Allogene Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Allogene Therapeutics, Inc.
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ...
Allogene Therapeutics Inc (ALLO) showcases significant progress in clinical trials and maintains a strong cash position, ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.28. Operator: Hello, and thank you for standing ...
Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What ...
Allogene Therapeutics Inc (NASDAQ:ALLO) is set to release its Q1 2025 earnings on May 13, 2025. The consensus estimate for Q1 2025 revenue is $0.00 million, and the earnings are expected to come ...
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, ...
ALLO | Allogene Therapeutics Inc. Profile | MarketWatch
Allogene Therapeutics Inc. 210 East Grand Avenue South San Francisco, California 94080-4811 Phone1 650 457-2700 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$22K ...
Allogene Therapeutics Inc. - Page 1 | BioWorld
BioWorld Content on 'Allogene Therapeutics Inc.'All gains made throughout the summer have vanished as the BioWorld Cancer Index (BCI) has hit its lowest point in 2022. Down 41.9% this year, BCI ...
Commit To Purchase Allogene Therapeutics At $2.50, Earn 32.6% ... - Nasdaq
So unless Allogene Therapeutics Inc sees its shares decline 11% and the contract is exercised (resulting in a cost basis of $2.25 per share before broker commissions, subtracting the 25 cents from ...
Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
Allogene Therapeutics, Inc. ALLO announced that the FDA has placed its clinical studies evaluating AlloCAR T-based cancer therapies on clinical hold. The decision was taken by the regulatory ...
Allogene Therapeutics Completes a $120 Million Private Financing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today ...
Similar Companies
Loading the latest forecasts...